| 代志强,唐福兴,杨静.核受体共激活因子 3、髓样细胞白血病 -1、程序性死亡受体配体 1的表达对甲状腺癌根治术后复发的预测价值[J].安徽医药,2026,30(6):1214-1218. |
| 核受体共激活因子 3、髓样细胞白血病 -1、程序性死亡受体配体 1的表达对甲状腺癌根治术后复发的预测价值 |
| The predictive value of nuclear receptor coactivator 3, myeloid cell leukemia-1, and programmed death-ligand 1 expression for recurrence after radical thyroidectomy |
| |
| DOI：10.3969/j.issn.1009-6469.2026.06.030 |
| 中文关键词: 甲状腺肿瘤 核受体共激活因子 3 髓样细胞白血病 -1 程序性死亡受体配体 1 术后复发 |
| 英文关键词: Thyroid neoplasms Nuclear receptor coactivator 3 Myeloid cell leukemia-1 Programmed death-ligand 1 Postop. erative recurrence |
| 基金项目: |
|
| 摘要点击次数: 45 |
| 全文下载次数: 17 |
| 中文摘要: |
| 目的为探究核受体共激活因子 3(NCOA3)、髓样细胞白血病 -1(MCL-1)、程序性死亡受体配体 1(PD-L1)在甲状腺癌病人血清中的表达及其对根治术后复发的预测价值。方法前瞻性选取 2022年 1月至 2024年 1月在保定市第二医院进行甲状腺癌根治术的甲状腺癌病人 81例作为观察组，另选取同时期在该院就诊的甲状腺良性病变病人 76例作为对照组；对甲状腺癌病人进行根治术治疗后随访 6个月，根据术后是否复发分为复发组(n=26)与未复发组(n=55)。以酶联免疫吸附分析(ELISA)检测血清 NCOA3、MCL-1、PD-L1水平；采用 Pearson相关性分析检验血清 NCOA3、MCL-1、PD-L1表达水平的相关性， logistic回归分析探索术后复发的相关因素；采用受试者操作特征曲线( ROC曲线)分析血清 NCOA3、MCL-1、PD-L1表达水平预测甲状腺癌病人根治术后复发的效能。结果观察组血清 NCOA3［(16.32±2.75)μg/L比( 12.57±3.04)μg/L］、 MCL-1［(61.48±12.91)μg/L比( 41.72±9.35)μg/L］、 PD-L1［(135.63±24.19)ng/L比( 115.76±18.26)ng/L］水平均显著高于对照组( P<0.05)；甲状腺癌病人血清 NCOA3与 MCL-1表达水平呈正相关( r=0.52，P<0.001)，血清 NCOA3与 PD-L1表达水平呈正相关( r=0.67，P<0.001)血清 MCL-1与 PD-L1表达水平呈正相关( r=0.64，P<0.001)；复发组发生淋巴结转移人数、 Ⅲ+Ⅳ期人数占比、血清 NCOA3［(19.25，±3.28)μg/ L比( 14.94±2.91)μg/L］、 MCL-1［( 67.02±6.11)μg/L比( 58.86±4.62)μg/L］、 PD-L1［( 148.17±14.34)ng/L比( 129.70±13.18)ng/L］水平显著高于未复发组( P<0.05)；高水平血清 NCOA3、MCL-1、PD-L1均是甲状腺癌病人根治术后复发的独立危险因素( P<0.05)；血清 NCOA3、MCL-1、PD-L1水平及三者联合预测甲状腺癌病人根治术后复发的曲线下面积( AUC)分别为 0.87、0.85、 0.90、0.98，三联合预测优于单独预测(均 P<0.05)。结论甲状腺癌复发病人血清 NCOA3、MCL-1、PD-L1水平高于无复发病人，三者水平变化可用于评估甲状腺癌病人预后情况。 |
| 英文摘要: |
| Objective To investigate the expression of nuclear receptor coactivator 3 (NCOA3), myeloid cell leukemia-1 (MCL-1), and programmed death-ligand 1 (PD-L1) in the serum of thyroid cancer patients and their predictive value for recurrence after radical surgery.Methods A prospective study was conducted. We prospectively selected 81 thyroid cancer patients who underwent radicalthyroidectomy at the Second Hospital of Baoding from January 2022 to January 2024 as the observation group, and 76 patients with be.nign thyroid lesions who were treated at the same hospital during the same period as the control group. Thyroid cancer patients were fol.lowed up for 6 months after radical surgery and were divided into the recurrence group (n=26) and the non-recurrence group (n=55) based on postoperative recurrence. Serum levels of NCOA3, MCL-1, and PD-L1 were measured using enzyme-linked immunosorbent assay (ELISA). Pearson correlation analysis was used to examine the correlation between serum NCOA3, MCL-1, and PD-L1 expressionlevels, logistic regression analysis was used to explore factors related to postoperative recurrence, and receiver operating characteristiccurve (ROC curve) analysis was used to evaluate the efficacy performance of serum NCOA3, MCL-1, and PD-L1 expression levels in predicting postoperative recurrence in thyroid cancer patients.Results Serum levels of NCOA3 [(16.32±2.75) μg/L vs. (12.57±3.04) μg/L], MCL-1 [(61.48±12.91) μg/L vs. (41.72±9.35) μg/L], and PD-L1 [(135.63±24.19) ng/L vs. (115.76±18.26) ng/L] in the observa. tion group were significantly higher than those in the control group (P<0.05). In thyroid cancer patients, serum NCOA3 level was posi. tively correlated with serum MCL-1 expression (r=0.52, P<0.001), serum NCOA3 level was positively correlated with serum PD-L1 level (r=0.67, P<0.001), and serum MCL-1 level was positively correlated with serum PD-L1 level (r=0.64, P<0.001). The recurrence grouphad a significantly higher number of patients with lymph node metastases, a higher proportion of patients with stage Ⅲ-Ⅳ disease, and higher serum levels of NCOA3 [(19.25±3.28) μg/L vs. (14.94±2.91) μg/L], MCL-1 [(67.02±6.11) μg/L vs. (58.86±4.62) μg/L], and PD-L1 [(148.17±14.34) ng/L vs. (129.70±13.18) ng/L] compared with the non-recurrence group (P<0.05). High serum levels of NCOA3, MCL-1, and PD-L1 were independent risk factors for postoperative recurrence in thyroid cancer patients (P<0.05). The areas under the curve (AUC) for predicting postoperative recurrence were 0.87 for serum NCOA3, 0.85 for serum MCL-1, 0.90 for serum PD-L1, and 0.98 for the combination of the three, respectively, with the combined prediction being superior to individual predictions (all P<0.05).Conclu. sion The serum levels of NCOA3, MCL-1, and PD-L1 are higher in patients with recurrent thyroid cancer than in those without recur.rence, and changes in the levels of these three markers can be used to assess the prognosis of thyroid cancer patients. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
